Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712075 | 0.76 | SMN1; SMN2 (0.53) | GAASMN1; SMN2THRBL3MBTL1MAPT | |
| SCHEMBL4848464 | 0.76 | SMN1; SMN2 (0.53) | GAASMN1; SMN2THRBL3MBTL1MAPT | |
| SCHEMBL15549899 | 0.75 | ELANE (0.54) | GAAATMELANETP53 | |
| SCHEMBL26854257 | 0.75 | KYNU (0.55) | GAAALDH1A1ATMELANETP53 | |
| SCHEMBL1239037 | 0.75 | KYNU (0.55) | GAAALDH1A1ATMELANETP53 | |
| SCHEMBL4856385 | 0.71 | MEN1 (0.44) | GAASMN1; SMN2THRBL3MBTL1MAPT | |
| SCHEMBL4856386 | 0.71 | MEN1 (0.44) | GAASMN1; SMN2THRBL3MBTL1MAPT | |
| SCHEMBL11388332 | 0.69 | CYP3A4 (0.46) | GAASMN1; SMN2THRBL3MBTL1MAPT | |
| SCHEMBL3434848 | 0.69 | ELANE (0.47) | GAAATMELANETP53 | |
| SCHEMBL4852735 | 0.69 | ALDH1A1 (0.58) | GAASMN1; SMN2THRBL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375244-B2 | Production method for aminophosphonic acid derivatives | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20070142658-A1 | Production method for aminophosphonic acid derivatives | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142658-A1 | Production method for aminophosphonic acid derivatives | AASDHPPT, NPEPPS, DAO | GAA 1150/4885SMN1; SMN2 2825/4885THRB 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.